Investors are increasingly scrutinizing the merits of two small-cap medical companies, Ekso Bionics (NASDAQ:EKSO) and LENSAR (NASDAQ:LNSR). A comprehensive analysis reveals significant differences in their institutional ownership, earnings, valuation, and analyst recommendations, which may influence future investment decisions.
Comparative Financial Performance
When examining the financial health of Ekso Bionics and LENSAR, key metrics such as gross revenue and earnings per share are crucial. For instance, Ekso Bionics has a gross revenue of approximately $5 million, while LENSAR reported around $15 million for its latest fiscal year. This disparity highlights LENSAR’s larger market presence.
In terms of institutional ownership, Ekso Bionics has 6.4% of its shares held by institutional investors. In contrast, LENSAR enjoys a much stronger position with 40.2% of its shares owned by these entities. Furthermore, company insiders hold 6.0% of Ekso Bionics, compared to a significant 66.0% for LENSAR. This level of insider ownership can indicate confidence in the company’s future performance.
Profitability and Risk Assessment
Profitability metrics for both companies reveal distinct advantages. Ekso Bionics has a net margin of -20%, while LENSAR boasts a healthier net margin of 10%. This suggests that LENSAR is currently more effective in converting revenue into profit.
Risk volatility also plays a vital role in investment decisions. Ekso Bionics has a beta of 0.82, indicating its share price is 18% less volatile than the S&P 500. LENSAR, with a beta of 0.66, demonstrates even less volatility at 34% below the index. This lower beta may attract risk-averse investors seeking stability.
Analysts have provided insights into the future potential of both companies. Ekso Bionics has a consensus target price of $10.50, suggesting a potential upside of 91.96%. LENSAR’s target price is set at $15.00, with a potential upside of 24.90%. The stronger upside for Ekso Bionics has led analysts to favor it over LENSAR in recent assessments.
Company Profiles
Founded in 2005, Ekso Bionics is headquartered in San Rafael, California. The company specializes in the design and development of exoskeleton products aimed at both medical and industrial markets. Its EksoHealth segment focuses on rehabilitation devices for patients with neurological impairments, while EksoWorks provides solutions for able-bodied workers performing strenuous tasks.
Conversely, LENSAR, incorporated in 2004 and based in Orlando, Florida, centers its operations on developing advanced laser systems for cataract surgery. The LENSAR Laser System incorporates proprietary technology that enhances the precision and efficiency of surgical procedures. The company also offers the ALLY Adaptive Cataract Treatment System, which combines advanced laser capabilities in a compact unit for optimal surgical performance.
In summary, while both Ekso Bionics and LENSAR operate within the medical device sector, their financial metrics and market positions differ significantly. The analysis suggests that Ekso Bionics may hold a slight edge in terms of future growth potential, but LENSAR shows robust profitability and stability. Investors should carefully consider these factors when evaluating opportunities in these companies.
